Source link : https://newshealth.biz/health-news/trial-changes-first-line-approach-for-most-common-breast-cancer-subtype/
(MedPage Today) — CHICAGO — Incorporating the investigational, oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of emerging ESR1 mutations extended the benefit of first-line therapy in hormone receptor (HR)-positive… Source link : https://www.medpagetoday.com/meetingcoverage/asco/115837 Author : Publish date : 2025-06-01 12:00:00 Copyright for syndicated content belongs to the linked Source.
The post Trial Changes First-Line Approach for Most Common Breast Cancer Subtype first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-01 12:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8